NEW YORK (GenomeWeb News) – Sanford-Burnham Medical Research Institute and Intrexon have struck a collaboration focused on developing new induced pluripotent stem cell technologies for research purposes, the institute said today.

Under the plan, Sanford-Burnham researchers will use Intrexon's RheoSwitch Therapeutic System (RTS) and its Laser-Enabled Analysis and Processing (LEAP) instrument for cellular selection and gene regulation purposes. Intrexon may obtain commercial and intellectual property rights to technologies that result from the partnership, Sanford-Burnham said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.